FDA approves mepolizumab for rare blood disorder
from Pharmacy Times
The FDA has approved mepolizumab for the treatment of patients aged 12 years and older with hypereosinophilic syndrome. HES is a group of rare disorders associated with higher than normal levels of a type of disease-fighting white blood cell with evidence of organ damage.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063